Open-label Treatment in Cushing's Syndrome

Status:
Active, not recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

This is a long-term, open-label extension study of levoketoconazole in subjects with endogenous Cushing's Syndrome.

Phase 3

Cortendo AB